A cell-penetrating, anti-inflammatory peptide developed byJacek Hawiger, Louise B. McGavock Chair and Distinguished Professor of Medicine, and licensed to biopharmaceutical companyAmytrx, has been approved by the FDA for testing as a potential therapeutic for mild to moderate eczema. The peptide, known as AMTX-100, has been in clinical trials since March Continue reading →

Details Category: Small Molecules Published on Friday, 30 October 2020 15:20 Hits: 102 Results were presented during the Late-Breaking News session of the European Academy of Dermatology and Venereology (EADV) Virtual 2020 BALLERUP, Denmark & MADISON, NJ, USA I October 29, 2020 I LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of a Phase 2b dose-finding study with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, during the Late Breaking News session of the European Academy of Dermatology and Venereology (EADV) Virtual 2020.1 Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.2,3 The cream formulation of delgocitinib is an investigational therapy under clinical development and has not been approved by any regulatory authority. The primary endpoint for the randomized, double-blind, vehicle-controlled, multi-center Phase 2b dose-finding trial was the proportion of adult patients with mild-to-severe CHE who achieved an Investigators Global Assessment (IGA)-CHE score of 0 (clear) or 1 (almost clear) with a 2 point improvement from baseline, at week 16.1 A key secondary endpoint was change in Hand Eczema Severity Index (HECSI) from baseline to week 16.1 The results presented today showed that delgocitinib cream demonstrated a statistically significant dose-response relationship for these endpoints compared to vehicle.1 Across all treatment groups, the majority of adverse events were non-serious, mild or moderate in severity and not considered treatment related.1 In addition, none of the three serious adverse events were considered treatment related,1 and the most frequently reported adverse events were nasopharyngitis, eczema and headache.1 "There is a significant unmet need for additional treatments for long-term control of CHE, which can cause considerable social and employment burden for both individuals and society, said Prof Continue reading →

Babies have sensitive skin and are more prone to skin problems. Here are some tips by Dr. Sirisha Singh, Dermatologist to help you take care of your babys skin during the winter weather Continue reading →